Cantor Fitzgerald Begins Coverage on Aphria (NYSE:APHA)

Equities researchers at Cantor Fitzgerald started coverage on shares of Aphria (NYSE:APHA) in a note issued to investors on Tuesday, Marketbeat reports. The firm set an “overweight” rating and a $10.40 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 110.10% from the stock’s current price.

A number of other brokerages have also recently commented on APHA. ValuEngine upgraded shares of Aphria from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Jefferies Financial Group set a $8.30 price target on shares of Aphria and gave the company a “buy” rating in a research note on Tuesday, October 15th. CIBC restated a “sell” rating and set a $6.50 price target on shares of Aphria in a research note on Wednesday, October 16th. Pi Financial set a $9.00 price target on shares of Aphria and gave the company a “buy” rating in a research note on Tuesday, October 15th. Finally, Zacks Investment Research upgraded shares of Aphria from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $11.38.

Aphria stock opened at $4.95 on Tuesday. Aphria has a twelve month low of $3.75 and a twelve month high of $13.45. The firm has a 50 day moving average price of $5.27 and a 200-day moving average price of $6.38. The company has a market capitalization of $1.29 billion, a P/E ratio of -45.00 and a beta of 2.83.

Aphria (NYSE:APHA) last released its earnings results on Tuesday, October 15th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.10. The company had revenue of $126.10 million for the quarter, compared to the consensus estimate of $131.15 million. Aphria’s quarterly revenue was up 848.1% on a year-over-year basis. As a group, research analysts expect that Aphria will post 0.07 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the stock. Synovus Financial Corp lifted its stake in shares of Aphria by 56.9% during the 2nd quarter. Synovus Financial Corp now owns 5,514 shares of the company’s stock valued at $39,000 after buying an additional 2,000 shares in the last quarter. Creative Planning lifted its stake in shares of Aphria by 2.9% during the 3rd quarter. Creative Planning now owns 74,332 shares of the company’s stock valued at $386,000 after buying an additional 2,073 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Aphria by 76.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,248 shares of the company’s stock worth $44,000 after purchasing an additional 2,698 shares in the last quarter. Sfmg LLC lifted its stake in Aphria by 15.0% in the 3rd quarter. Sfmg LLC now owns 28,607 shares of the company’s stock worth $148,000 after purchasing an additional 3,737 shares in the last quarter. Finally, Wedbush Securities Inc. lifted its stake in Aphria by 40.6% in the 3rd quarter. Wedbush Securities Inc. now owns 15,070 shares of the company’s stock worth $78,000 after purchasing an additional 4,350 shares in the last quarter. Institutional investors own 10.94% of the company’s stock.

Aphria Company Profile

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Read More: 12b-1 Fees

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.